An optimized expression vector for improving the yield of dengue virus-like particles from transfected insect cells.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Virological Methods

• Publication date

  2014-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.jviromet.2014.04.019PMID 24814967
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immature and Mature Dengue Serotype 1 Virus Structures Provide Insight into the Maturation Process

  2013cited by this paper
• Next generation dengue vaccines: a review of candidates in preclinical development.

  2011cited by this paper
• From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.

  2011cited by this paper
• A Summary of

  2011cited by this paper
• Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice

  2011cited by this paper
• Recombinant dengue virus-like particles from Pichia pastoris: efficient production and immunological properties

  2010cited by this paper
• Influence of pr-M Cleavage on the Heterogeneity of Extracellular Dengue Virus Particles

  2010cited by this paper
• Evaluation of Extracellular Subviral Particles of Dengue Virus Type 2 and Japanese Encephalitis Virus Produced by Spodoptera frugiperda Cells for Use as Vaccine and Diagnostic Antigens

  2010cited by this paper
• Immunodominance and Functional Activities of Antibody Responses to Inactivated West Nile Virus and Recombinant Subunit Vaccines in Mice

  2010cited by this paper
• Efficient Assembly and Secretion of Recombinant Subviral Particles of the Four Dengue Serotypes Using Native prM and E Proteins

  2009cited by this paper
• Differential Modulation of prM Cleavage, Extracellular Particle Distribution, and Virus Infectivity by Conserved Residues at Nonfurin Consensus Positions of the Dengue Virus pr-M Junction

  2008cited by this paper
• Rare Codons Cluster

  2008cited by this paper
• Enzyme-Linked Immunosorbent Assays Using Novel Japanese Encephalitis Virus Antigen Improve the Accuracy of Clinical Diagnosis of Flavivirus Infections

  2008cited by this paper
• A detailed mutagenesis study of flavivirus cross-reactive epitopes using West Nile virus-like particles.

  2007cited by this paper
• A single M protein mutation affects the acid inactivation threshold and growth kinetics of a chimeric flavivirus.

  2007cited by this paper
• Mutation analysis of the fusion domain region of St. Louis encephalitis virus envelope protein.

  2007cited by this paper
• Antibody Recognition and Neutralization Determinants on Domains I and II of West Nile Virus Envelope Protein

  2006cited by this paper
• Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus

  2005cited by this paper
• Secretion of noninfectious dengue virus-like particles and identification of amino acids in the stem region involved in intracellular retention of envelope protein.

  2005cited by this paper
• Structural basis of West Nile virus neutralization by a therapeutic antibody

  2005cited by this paper
• Inefficient Signalase Cleavage Promotes Efficient Nucleocapsid Incorporation into Budding Flavivirus Membranes

  2004cited by this paper
• Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus.

  2003cited by this paper
• Production of anti-dengue NS1 monoclonal antibodies by DNA immunization.

  2003cited by this paper
• Identification of Neutralizing Epitopes within Structural Domain III of the West Nile Virus Envelope Protein

  2002cited by this paper
• Structure of dengue virus: implications for flavivirus organization, maturation, and fusion.

  2002cited by this paper
• Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine.

  2002cited by this paper
• Construction of infectious dengue 2 virus cDNA clones using high copy number plasmid.

  2001cited by this paper
• West Nile Virus Recombinant DNA Vaccine Protects Mouse and Horse from Virus Challenge and Expresses In Vitro a Noninfectious Recombinant Antigen That Can Be Used in Enzyme-Linked Immunosorbent Assays

  2001cited by this paper
• Generation and Characterization of a Mammalian Cell Line Continuously Expressing Japanese Encephalitis Virus Subviral Particles

  2001cited by this paper
• Mutational Evidence for an Internal Fusion Peptide in Flavivirus Envelope Protein E

  2001cited by this paper
• Codon usage tabulated from international DNA sequence databases: status for the year 2000

  2000cited by this paper
• Construction of modular and versatile plasmid vectors for the high-level expression of single or multiple genes in insects and insect cell lines.

  1999cited by this paper
• Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form

  1995cited by this paper
• Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence.

  1982cited by this paper
• Isolation of a Singh's Aedes albopictus cell clone sensitive to Dengue and Chikungunya viruses.

  1978cited by this paper

• Multiscale Simulations and Cryo-Electron Microscopy Reveal the Transition Pathway of Dengue Virus-like Particle Nanoassembly.

  2026cites this paper
• Opportunities and Challenges of mRNA and VLP Technologies for Pan-Flavivirus Vaccine Development: Focus on Conserved Quaternary Epitope Conformations

  2026cites this paper
• Overcoming dengue vaccine challenges through next-generation virus-like particle immunization strategies

  2025cites this paper
• Production of Envelope Protein-Based Virus-like Particles of DENV‑2 in E. coli and Investigation of Their Binding Interactions with Gallic Acid Derivatives of Glucose as Potential Drug Candidates

  2025cites this paper
• Heterologous prime-boost immunization induces protection against dengue virus infection in cynomolgus macaques

  2023cites this paper
• A group of infection-enhancing and focus size-reducing monoclonal antibodies recognized an ‘a and c’ strands epitope in the pr domain of Dengue Virus prM

  2022cites this paper
• An Examination of the Safety and Efficacy of Aripo-Zika as a Zika Virus Vaccine Candidate

  2022cites this paper
• Flavivirus vaccines: Virus-like particles and single-round infectious particles as promising alternatives.

  2021cites this paper
• Plant‐made dengue virus‐like particles produced by co‐expression of structural and non‐structural proteins induce a humoral immune response in mice

  2020cites this paper
• Recent Advances in the Development of Virus-Like Particle-Based Flavivirus Vaccines

  2020cites this paper
• Development and optimization of a Zika virus antibody-dependent cell-mediated cytotoxicity (ADCC) assay.

  2020cites this paper
• Enhanced production of infectious particles by adaptive modulation of C-prM processing and C-C interaction during propagation of dengue pseudoinfectious virus in stable CprME-expressing cells.

  2019cites this paper
• Formation of Virus-Like Particles of the Dengue Virus Serotype 2 Expressed in Silkworm Larvae

  2019cites this paper
• An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design

  2017cites this paper
• MMP 1-1 Generation and Characterization of DENV-1 / 2 EDIII Chimeric Virus like-Particles การสร้างและศึกษาคุณสมบัติของอนุภาคคล้ายไวรัสลูกผสม ระหว่างเช้ือไวรัสเด็งกี ่ชนิดที ่ 1 และ ชนิดที ่ 2

  2016cites this paper
• Generation and preclinical immunogenicity study of dengue type 2 virus-like particles derived from stably transfected mosquito cells.

  2015cites this paper
• Bioreactor concepts for cell culture-based viral vaccine production

  2015cites this paper